First Manhattan’s Roivant Sciences ROIV Stock Holding History

First Manhattan’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$394K	Hold	11,146	–	–	﹤0.01%	617
2026 Q1	$309K	Hold	11,146	–	–	﹤0.01%	656
2025 Q4	$242K	Sell	11,146 -954	-8%	-$18.8K	﹤0.01%	674
2025 Q3	$183K	Hold	12,100	–	–	﹤0.01%	689
2025 Q2	$136K	Hold	12,100	–	–	﹤0.01%	679
2025 Q1	$122K	Hold	12,100	–	–	﹤0.01%	656
2024 Q4	$143K	Buy	12,100 +200	+2%	+$2.37K	﹤0.01%	664
2024 Q3	$137K	Buy	11,900 +500	+4%	+$5.69K	﹤0.01%	663
2024 Q2	$120K	Hold	11,400	–	–	﹤0.01%	646
2024 Q1	$120K	Buy	11,400 +400	+4%	+$4.31K	﹤0.01%	738
2023 Q4	$124K	Hold	11,000	–	–	﹤0.01%	726
2023 Q3	$128K	Hold	11,000	–	–	﹤0.01%	730
2023 Q2	$111K	Hold	11,000	–	–	﹤0.01%	749
2023 Q1	$81.2K	Buy	+11,000	New	+$90.6K	﹤0.01%	838

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

First Manhattan's ROIV Position: Q2 2026 in Review

First Manhattan held its Roivant Sciences (ROIV) position steady in Q2 2026 at 11,146 shares worth $394K. The position accounts for ﹤0.01% of the portfolio, ranked #617.

First Manhattan first reported a position in ROIV in Q1 2023 and has held it in 14 quarters since. 499 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

First Manhattan held 11,146 shares of Roivant Sciences worth $394K as of Q2 2026.
First Manhattan left its Roivant Sciences share count unchanged in Q2 2026.
Roivant Sciences made up ﹤0.01% of First Manhattan's portfolio in Q2 2026, its #617 holding.
First Manhattan first reported a position in Roivant Sciences in Q1 2023 and has held it in 14 quarters since.
499 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on First Manhattan's 13F filing for Q2 2026, filed 14 Aug 2026.